Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

RaySearch Laboratories

DB:27R
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
27R
DB
SEK2B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

RaySearch Laboratories AB (publ) develops software solutions for cancer treatment in Sweden and internationally. The last earnings update was 45 days ago. More info.


Add to Portfolio Compare Print
  • RaySearch Laboratories has significant price volatility in the past 3 months.
27R Share Price and Events
7 Day Returns
8.1%
DB:27R
4.1%
DE Healthcare Services
7.3%
DE Market
1 Year Returns
-49.5%
DB:27R
0.9%
DE Healthcare Services
-17.7%
DE Market
27R Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
RaySearch Laboratories (27R) 8.1% -35.7% -51.8% -49.5% - -
DE Healthcare Services 4.1% -8.3% -18.1% 0.9% 24.9% 85.3%
DE Market 7.3% -17.9% -25.8% -17.7% -25.6% -29%
1 Year Return vs Industry and Market
  • 27R underperformed the Healthcare Services industry which returned 0.9% over the past year.
  • 27R underperformed the Market in Germany which returned -17.7% over the past year.
Price Volatility
27R
Industry
5yr Volatility vs Market

Value

 Is RaySearch Laboratories undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of RaySearch Laboratories to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for RaySearch Laboratories.

DB:27R Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:27R
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 0.97
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.973 (1 + (1- 22%) (8.81%))
1.026
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.026 * 5.44%)
5.19%

Discounted Cash Flow Calculation for DB:27R using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for RaySearch Laboratories is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:27R DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 5.19%)
2020 38.00 Analyst x1 36.12
2021 48.00 Analyst x1 43.38
2022 67.00 Analyst x1 57.56
2023 60.65 Est @ -9.48% 49.53
2024 56.55 Est @ -6.76% 43.90
2025 53.81 Est @ -4.85% 39.71
2026 51.92 Est @ -3.51% 36.42
2027 50.58 Est @ -2.57% 33.74
2028 49.61 Est @ -1.92% 31.45
2029 48.89 Est @ -1.46% 29.46
Present value of next 10 years cash flows SEK401.00
DB:27R DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK48.89 × (1 + -0.39%) ÷ (5.19% – -0.39%)
SEK872.11
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK872.11 ÷ (1 + 5.19%)10
SEK525.61
DB:27R Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK401.00 + SEK525.61
SEK926.61
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK926.61 / 34.28
SEK27.03
DB:27R Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:27R represents 0.08814x of OM:RAY B
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.08814x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 27.03 x 0.08814
€2.38
Value per share (EUR) From above. €2.38
Current discount Discount to share price of €4.98
= -1 x (€4.98 - €2.38) / €2.38
-109%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of RaySearch Laboratories is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for RaySearch Laboratories's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are RaySearch Laboratories's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:27R PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK1.47
OM:RAY B Share Price ** OM (2020-03-30) in SEK SEK56.5
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.1x
Germany Market PE Ratio Median Figure of 400 Publicly-Listed Companies 16.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of RaySearch Laboratories.

DB:27R PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:RAY B Share Price ÷ EPS (both in SEK)

= 56.5 ÷ 1.47

38.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RaySearch Laboratories is overvalued based on earnings compared to the DE Healthcare Services industry average.
  • RaySearch Laboratories is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does RaySearch Laboratories's expected growth come at a high price?
Raw Data
DB:27R PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 38.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
29.1%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.29x
Germany Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

DB:27R PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 38.44x ÷ 29.1%

1.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RaySearch Laboratories is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on RaySearch Laboratories's assets?
Raw Data
DB:27R PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK20.58
OM:RAY B Share Price * OM (2020-03-30) in SEK SEK56.5
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.88x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.43x
DB:27R PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:RAY B Share Price ÷ Book Value per Share (both in SEK)

= 56.5 ÷ 20.58

2.75x

* Primary Listing of RaySearch Laboratories.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RaySearch Laboratories is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess RaySearch Laboratories's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. RaySearch Laboratories has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is RaySearch Laboratories expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is RaySearch Laboratories expected to grow at an attractive rate?
  • RaySearch Laboratories's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • RaySearch Laboratories's earnings growth is expected to exceed the Germany market average.
  • RaySearch Laboratories's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:27R Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:27R Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 29.1%
DB:27R Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 12.3%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 28.6%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:27R Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:27R Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 1,077 315 122 2
2021-12-31 971 272 94 2
2020-12-31 854 248 66 2
2020-03-30
DB:27R Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 742 320 50
2019-09-30 727 360 64
2019-06-30 733 295 85
2019-03-31 684 173 84
2018-12-31 627 178 79
2018-09-30 613 105 118
2018-06-30 574 153 104
2018-03-31 575 164 103
2017-12-31 585 147 118
2017-09-30 571 175 121
2017-06-30 586 149 151
2017-03-31 563 138 160

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • RaySearch Laboratories's earnings are expected to grow significantly at over 20% yearly.
  • RaySearch Laboratories's revenue is expected to grow by 12.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:27R Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from RaySearch Laboratories Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:27R Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 3.56 4.36 2.75 2.00
2021-12-31 2.74 3.31 2.17 2.00
2020-12-31 1.94 1.96 1.91 2.00
2020-03-30
DB:27R Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 1.47
2019-09-30 1.87
2019-06-30 2.49
2019-03-31 2.45
2018-12-31 2.29
2018-09-30 3.46
2018-06-30 3.02
2018-03-31 3.01
2017-12-31 3.43
2017-09-30 3.53
2017-06-30 4.40
2017-03-31 4.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • RaySearch Laboratories is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess RaySearch Laboratories's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
RaySearch Laboratories has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has RaySearch Laboratories performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare RaySearch Laboratories's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • RaySearch Laboratories's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • RaySearch Laboratories's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • RaySearch Laboratories's 1-year earnings growth is negative, it can't be compared to the DE Healthcare Services industry average.
Earnings and Revenue History
RaySearch Laboratories's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from RaySearch Laboratories Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:27R Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 741.58 50.41 445.56 174.67
2019-09-30 726.53 64.12 437.84 168.15
2019-06-30 732.66 85.15 405.45 159.02
2019-03-31 684.04 83.91 384.36 151.89
2018-12-31 627.22 78.52 353.89 147.69
2018-09-30 612.74 118.16 313.49 134.58
2018-06-30 573.96 103.64 296.97 124.01
2018-03-31 574.56 103.13 277.86 114.56
2017-12-31 585.09 117.63 268.10 104.30
2017-09-30 571.48 121.26 252.11 102.10
2017-06-30 585.51 151.18 246.65 100.44
2017-03-31 562.86 159.92 232.95 98.26
2016-12-31 531.47 151.41 223.13 93.21
2016-09-30 472.07 108.80 217.66 88.57
2016-06-30 446.91 94.39 203.42 92.34
2016-03-31 405.27 62.95 193.11 96.25
2015-12-31 397.60 70.21 181.60 101.51
2015-09-30 373.43 77.59 157.60 105.38
2015-06-30 344.46 76.32 140.11 99.95
2015-03-31 318.97 78.92 120.69 96.36
2014-12-31 285.22 59.83 109.17 95.07
2014-09-30 267.55 24.23 140.98 95.65
2014-06-30 234.90 -4.08 137.59 95.62
2014-03-31 210.55 -20.08 135.95 94.14
2013-12-31 204.47 -20.84 133.13 90.72
2013-09-30 191.24 -0.57 97.34 84.51
2013-06-30 192.48 13.08 87.36 81.46
2013-03-31 191.54 20.42 81.85 78.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • RaySearch Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • RaySearch Laboratories used its assets less efficiently than the DE Healthcare Services industry average last year based on Return on Assets.
  • RaySearch Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess RaySearch Laboratories's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
RaySearch Laboratories has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is RaySearch Laboratories's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up RaySearch Laboratories's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • RaySearch Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • RaySearch Laboratories's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of RaySearch Laboratories's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 11.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from RaySearch Laboratories Company Filings, last reported 2 months ago.

DB:27R Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 705.47 49.52 113.86
2019-09-30 686.86 49.44 107.48
2019-06-30 694.39 12.32 118.13
2019-03-31 672.58 94.42 113.17
2018-12-31 657.45 124.28 112.20
2018-09-30 624.96 122.00 52.89
2018-06-30 611.44 82.75 69.15
2018-03-31 592.33 83.17 117.87
2017-12-31 580.43 83.78 104.16
2017-09-30 508.13 38.93 69.59
2017-06-30 508.25 49.32 70.17
2017-03-31 486.84 51.56 84.43
2016-12-31 460.19 50.00 87.72
2016-09-30 385.94 0.00 29.84
2016-06-30 356.64 0.00 33.53
2016-03-31 337.76 0.00 54.64
2015-12-31 319.52 25.00 59.71
2015-09-30 286.45 0.00 47.58
2015-06-30 272.41 0.00 53.91
2015-03-31 273.74 0.00 64.54
2014-12-31 251.55 25.00 56.09
2014-09-30 213.23 0.00 24.78
2014-06-30 201.45 0.00 27.01
2014-03-31 202.51 0.00 34.75
2013-12-31 196.60 0.00 38.23
2013-09-30 192.10 0.00 33.86
2013-06-30 205.83 0.00 42.62
2013-03-31 222.70 0.00 62.29
  • RaySearch Laboratories's level of debt (7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (9.8% vs 7% today).
  • Debt is well covered by operating cash flow (646.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 12.3x coverage).
X
Financial health checks
We assess RaySearch Laboratories's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. RaySearch Laboratories has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is RaySearch Laboratories's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from RaySearch Laboratories dividends. Estimated to be 1.24% next year.
If you bought €2,000 of RaySearch Laboratories shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate RaySearch Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate RaySearch Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:27R Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:27R Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.90 2.00
2021-12-31 0.60 2.00
2020-12-31 0.50 1.00
2020-03-30
DB:27R Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2017-11-22 0.000 0.000
2017-08-24 0.000 0.000
2017-05-19 0.000 0.000
2017-04-28 0.000 0.000
2017-02-17 0.000 0.000
2016-04-15 0.250 0.162
2012-11-16 0.000 0.000
2012-08-28 0.000 0.000
2012-05-23 0.000 0.000
2012-02-16 0.000 0.000
2011-05-25 0.500 2.860
2010-04-22 0.500 1.365
2009-11-20 0.000 0.000
2009-08-27 0.000 0.000
2009-05-15 0.000 0.000
2009-04-20 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as RaySearch Laboratories has not reported any payouts.
  • Unable to verify if RaySearch Laboratories's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of RaySearch Laboratories's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as RaySearch Laboratories has not reported any payouts.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.2x coverage).
X
Income/ dividend checks
We assess RaySearch Laboratories's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can RaySearch Laboratories afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. RaySearch Laboratories has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of RaySearch Laboratories's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Johan Löf
COMPENSATION SEK8,210,000
AGE 50
TENURE AS CEO 20.2 years
CEO Bio

Dr. Johan Löf has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Löf serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Löf has been a Director of RaySearch Medical and Raysearch Laboratories AB since 2000. As a Doctoral Student, he worked with mathematical models for optimization ofradiation therapy and also developed theprototype for ORBIT. He served as a Director of RayIncentive AB. Dr. Löf has an MS in Engineering Physics from the Royal Institute of Technology (KTH Kungliga Tekniska Högskolan) and a Ph.D from the Department of Medical Radiation Physics at the Department of Oncology-Pathology, Karolinska Institutet.

CEO Compensation
  • Johan's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Johan's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the RaySearch Laboratories management team in years:

4.5
Average Tenure
46
Average Age
  • The tenure for the RaySearch Laboratories management team is about average.
Management Team

Johan Löf

TITLE
Founder
COMPENSATION
SEK8M
AGE
50
TENURE
20.2 yrs

Peter Thysell

TITLE
Chief Financial Officer
AGE
49
TENURE
4.7 yrs

Kjell Eriksson

TITLE
Chief Science Officer
AGE
46
TENURE
4.5 yrs

Petra Jansson

TITLE
General Counsel
AGE
46
TENURE
2.7 yrs

Peter Kemlin

TITLE
Director of Sales & Marketing
AGE
45

Björn Hårdemark

TITLE
Deputy Chief Executive Officer
AGE
42
TENURE
4.5 yrs

Fredrik Löfman

TITLE
Head of Machine Learning
TENURE
0.2 yrs

Marc Mlyn

TITLE
President of Raysearch Americas Inc
Board of Directors Tenure

Average tenure and age of the RaySearch Laboratories board of directors in years:

15.8
Average Tenure
58
Average Age
  • The average tenure for the RaySearch Laboratories board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Lars Wollung

TITLE
Chairman of the Board
AGE
58
TENURE
0.8 yrs

Johan Löf

TITLE
Founder
COMPENSATION
SEK8M
AGE
50
TENURE
20.2 yrs

Carl Bergendal

TITLE
Independent Director
COMPENSATION
SEK480K
AGE
74
TENURE
20.2 yrs

Hans Wigzell

TITLE
Independent Director
COMPENSATION
SEK250K
AGE
81
TENURE
15.8 yrs

Radhe Mohan

TITLE
Member of Scientific Advisory Board
TENURE
17.2 yrs

Anders Forsgren

TITLE
Member of Scientific Advisory Board

Anders Brahme

TITLE
Member of Scientific Advisory Board
AGE
75

David Jaffray

TITLE
Member of Scientific Advisory Board

Johanna Öberg

TITLE
Independent Director
COMPENSATION
SEK250K
AGE
44
TENURE
2.8 yrs

Britta Wallgren

TITLE
Independent Director
COMPENSATION
SEK147K
AGE
56
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Sep 19 Sell Henrik Friberger Individual 02. Sep 19 03. Sep 19 -7,299 €15.28 €-111,215
30. Aug 19 Sell Johan Löf Individual 27. Aug 19 30. Aug 19 -200,000 €17.24 €-3,227,208
29. Aug 19 Sell Carl Bergendal Individual 27. Aug 19 27. Aug 19 -5,000 €17.36 €-86,786
X
Management checks
We assess RaySearch Laboratories's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. RaySearch Laboratories has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

RaySearch Laboratories AB (publ) develops software solutions for cancer treatment in Sweden and internationally. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, reduce OAR dose, robustness, the physician's toolbox, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomo therapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, a oncology information system for the treatment of cancer comprising oncology treatment activities, including digital oncology workflows, rule-based scheduling, state-of-the-art software platform, enterprise-wide integration, adaptive therapy, and data handling and machine learning. In addition, it provides training courses, as well as customer support services. The company was founded in 2000 and is headquartered in Stockholm, Sweden.

Details
Name: RaySearch Laboratories AB (publ)
27R
Exchange: DB
Founded: 2000
SEK175,169,406
34,282,773
Website: http://www.raysearchlabs.com
Address: RaySearch Laboratories AB (publ)
Sveavägen 44,
Stockholm,
Stockholm County, 111 34,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM RAY B Class B Shares OMX Nordic Exchange Stockholm SE SEK 02. Jun 2003
OTCPK RSLB.F Class B Shares Pink Sheets LLC US USD 02. Jun 2003
DB 27R Class B Shares Deutsche Boerse AG DE EUR 02. Jun 2003
LSE 0GRZ Class B Shares London Stock Exchange GB SEK 02. Jun 2003
BATS-CHIXE RAYBS Class B Shares BATS 'Chi-X Europe' GB SEK 02. Jun 2003
Number of employees
Current staff
Staff numbers
376
RaySearch Laboratories employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/30 22:48
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/02/28
Last earnings filing: 2020/02/14
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.